Logo image
Back
Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis
Journal article   Open access

Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis

Zohaib Ahmed, Amna Iqbal, Sami Ghazaleh, Abdallah Kobeissy, Ali Nawras, Yaseen Alastal, Hani Saad, Sarmed Mansur, Idrees Mohiuddin, Umair Iqbal, …
Gastroenterology research, v 19(2), pp 64-72
01 Apr 2026
DOI: https://doi.org/10.14740/gr2108
Featured in Collection :   Drexel's Newest Publications
url
https://doi.org/10.14740/gr2108View
Published, Version of Record (VoR) Open

Abstract

Gastroenterology & Hepatology Life Sciences & Biomedicine Science & Technology
Background: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has remarkably increased in the past few years as they have demonstrated significant reduction inA1c and major cardiovascular outcomes and have led to weight loss with low risk of hypoglycemia. GLP-1 RA use has raised concerns about potential associations with increased gastric retention and adverse outcomes in upper endoscopy procedures. Methods: We conducted a comprehensive search across multiple databases to identify comparative studies evaluating the impact of GLP-1 RA exposure versus non-exposure on upper endoscopy outcomes. Studies comparing GLP-1 RAs to other medications were excluded. The primary outcome was the presence of retained gastric contents, with secondary outcomes including aspiration risk and the need for repeated esophagogastroduodenoscopy (EGD). Results: Our systematic review included 28 studies, comprising data from 212,082 individuals collected between 2015 and 2023. The meta-analysis revealed that GLP-1 RA use was associated with approximately four times higher odds of retained gastric contents compared to non-exposure (odds ratio (OR): 3.95, confidence interval (CI): 2.691-5.815, P < 0.0001, I2: 82.71%). There were no increased odds of aspiration (OR: 1.09, CI: 0.459-2.600, P = 0.145, I2: 91.44%) or repeated upper endoscopies (OR: 1.82, CI: 0.813-4.085, P = 0.145, I2: 85.32%). However, GLP-1 RA use was significantly associated with increased odds of procedure cancellation (OR: 3.96, CI: 2.870-5.563, P < 0.0001, I2: 4.19%). Conclusion: While GLP-1 RAs do not increase the risk of aspiration or necessitate repeated procedures, they are linked to a higher incidence of retained gastric contents and procedure cancellations. Further randomized controlled trials are necessary to better understand the effects of GLP-1 RAs on upper endoscopy outcomes.

Metrics

1 Record Views

Details

Logo image